In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary

  

ruxolitinib phosphate  Patient Information
The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms:oral JAK inhibitor INCB18424
oral Janus-associated kinase inhibitor INCB18424
US brand name:Jakafi
Code name:INCB18424